TKNO Quote, Financials, Valuation and Earnings

Geron has a net margin of -61.73% compared to Alpha Teknova's net margin of -53.33%. Alpha Teknova's return on equity of -31.69% beat Geron's return on equity of -59.29%.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 96.78%. On the other hand Geron has an analysts' consensus of $4.50 which suggests that it could grow by 226.09%. Given that Geron has higher upside potential than Alpha Teknova, analysts believe Geron is more attractive than Alpha Teknova.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Geron has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.916%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are smaller than Geron quarterly revenues of $47.5M. Alpha Teknova's net income of -$5.7M is higher than Geron's net income of -$25.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.92x versus 11.58x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -61.73% compared to Alpha Teknova's net margin of -49.65%. Alpha Teknova's return on equity of -31.69% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 96.78%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that Alpha Teknova has higher upside potential than NovaBay Pharmaceuticals, analysts believe Alpha Teknova is more attractive than NovaBay Pharmaceuticals.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Alpha Teknova's net income of -$5.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Alpha Teknova's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.92x versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -61.73% compared to Alpha Teknova's net margin of -2357.27%. Alpha Teknova's return on equity of -31.69% beat Palatin Technologies's return on equity of --.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 96.78%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Alpha Teknova, analysts believe Palatin Technologies is more attractive than Alpha Teknova.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Alpha Teknova's net income of -$5.7M is lower than Palatin Technologies's net income of -$2.4M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.92x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics has a net margin of -61.73% compared to Alpha Teknova's net margin of -296.76%. Alpha Teknova's return on equity of -31.69% beat Zevra Therapeutics's return on equity of -208.85%.

Alpha Teknova has a consensus price target of $10.67, signalling upside risk potential of 96.78%. On the other hand Zevra Therapeutics has an analysts' consensus of $21.63 which suggests that it could grow by 213.41%. Given that Zevra Therapeutics has higher upside potential than Alpha Teknova, analysts believe Zevra Therapeutics is more attractive than Alpha Teknova.

Alpha Teknova has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zevra Therapeutics has a beta of 1.938, suggesting its more volatile than the S&P 500 by 93.751%.

Alpha Teknova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova pays -- of its earnings as a dividend. Zevra Therapeutics pays out -- of its earnings as a dividend.

Alpha Teknova quarterly revenues are $9.3M, which are smaller than Zevra Therapeutics quarterly revenues of $12M. Alpha Teknova's net income of -$5.7M is higher than Zevra Therapeutics's net income of -$35.7M. Notably, Alpha Teknova's price-to-earnings ratio is -- while Zevra Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova is 6.92x versus 13.51x for Zevra Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.